Journal of Clinical Lipidology (2014) 8, 612–617

Journal of Clinical Lipidology

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled study

Adam M. Bernstein, MD, ScD*, **Michael F. Roizen, M[illegible]uis Mar[illegible]ez, MD, MPH**

Wellness Institute, Cleveland Clinic, Lyndhurst, OH, USA (Drs B[illegible] and Roizen), and Xyrion Medical Institute, Ponce, PR, USA (Dr Martinez)

KEYWORDS:
Palmitoleic acid;
Palmitoleate;
Omega-7;
Inflammation;
C-reactive protein;
Hyperlipidemia;
Cholesterol;
Lipids;
Supplementation

BACKGROUND: Purified palmitoleic acid (16:1, omega-7) has shown lipid-lowering and anti-inflammatory benefits in [illegible]bel, epidemiologic, and animal studies.

OBJECTIVE: Our objective w[illegible]form the first randomized controlled trial of purified palmitoleic acid supplementation [illegible]hum[illegible].

METHODS: [illegible]lts with [illegible]idemia and evidence of mild systemic inflammation (high-sensitivity C-reactive [illegible]ten[illegible]s-CRP] between 2 and 5 mg/L) were randomly allocated to receive either 220.5 m[illegible] *cis*-pa[illegible]itoleic ac[illegible] (n = 30) or an identical capsule with placebo (1000 mg of medium chain tr[illegible]erid[illegible]ce per day for 30 days. Participants were asked to maintain their current di[illegible]. Serum[illegible]s and hs-CRP were drawn at baseline and study completion.

RESULTS: [illegible]0 days, there were significant mean (95% confidence interval [CI]) reductions in [illegible] (−1.9 [−2[illegible] −1.4] mg/L), triglyceride (−30.2 [−40.2 to −25.3] mg/dL), and low-density lip[illegible]tein (LDL) (−8.9 [−12.0 to −5.8] mg/dL), and a significant increase in high-density lipoprotein ([illegible]) (2.4 [1.5, 3.3] mg/dL) in the intervention group compared with control. These changes equated [illegible]4%, 15%, and 8% reductions in CRP, triglyceride, and LDL respectively, and a 5% increase in HDL compared with control.

CONCLUSIONS: Purified palmitoleic acid may be useful in the treatment of hypertriglyceridemia [illegible] the beneficial added effects of decreasing LDL and hs-CRP and raising HDL. Further study is needed to elucidate mechanisms and establish appropriate human doses.

Tersus Pharmaceuticals funded the study and provided the experimental capsules, called *Provinal*, and the placebo capsules.

Michael F. Roizen is chair of the Scientific Advisory Board of Tersus Pharmaceuticals and chair of the Cleveland Clinic Wellness Institute. Adam M. Bernstein is a staff member of the Wellness Institute.

The authors thank James Bena and Katrina Zell for their assistance with the statistical analyses.

* Corresponding author. Wellness Institute, Cleveland Clinic, 1950 Richmond Road/TR2-203, Lyndhurst, OH 44124.

E-mail address: bernsta2@ccf.org

Submitted February 20, 2014. Accepted for publication August 6, 2014.

1933-2874
http://dx.doi.org/10.1016/j.jacl.2014.08.001

Introduction

Fat metabolism and glucose homeostasis are highly interconnected processes that contribute to the pathogenesis of insulin resistance and type 2 diabetes.[1] At the cellular level, diet-derived fat enters the circulation and is taken up by adipocytes, where it is metabolized through mitochondrial beta-oxidation or stored as triglyceride. Palmitoleic acid, or palmitoleate (16:1, n-7), synthesized from the breakdown of triglyceride or de novo from surplus carbohydrate, has recently been identified as a lipokine, an adipose tissue–derived lipid hormone that acts on liver and muscle tissue.[1,2] Epidemiological data suggest that circulating palmitoleate is involved in insulin sensitivity, cholesterol metabolism, and hemostasis, although the net cardiovascular effect may be mixed: lower low-density lipoprotein cholesterol (LDL), higher high-density lipoprotein cholesterol (HDL), lower fibrinogen, but higher triglycerides and greater insulin resistance, at least in men.[3] De novo biosynthesis of palmitoleate occurs in the liver as the liver converts excess carbohydrate into fat for long-term storage, and adipose-derived palmitoleate appears to suppress hepatic fatty acid synthesis, suggesting that the endogenous source(s) of palmitoleate—hepatic or adipose—may be the cause, or result, of reported divergent cardiovascular effects.[3]

Dairy[4,5] products are rich sources of *trans*-palmitoleate, whereas macadamia nuts[6–9] and certain fish[10] may contain the *cis* isomer. In epidemiologic studies, higher intake of the *trans* isomer from dairy has been associated with lower levels of inflammation and a lower risk of diabetes, but with mixed relationships to serum lipids.[4,5] In most,[7] but not all,[6] studies, macadamia nuts are associated with more favorable serum lipid profiles. Whether these divergent effects are due to the palmitoleate or other of its nutrients found in these foods remains uncertain. Animal studies have shown beneficial effects of supplemental palmitoleate alone on liver and plasma lipids.[11,12] In vivo studies have also demonstrated that palmitoleate induces beta-cell proliferation and improves secretory function in both animals[13] and humans.[14]

Our objective was to conduct the first randomized controlled trial of purified palmitoleic acid supplementation in humans. We hypothesized that supplementation would improve lipid profiles and decrease inflammation.

Methods

Design

We conducted a 30-day parallel, double-blinded, randomized, placebo-controlled study with 60 healthy participants. The study was carried out at Xyrion Medical Institute, a private clinic and research center in Ponce, Puerto Rico, and approved by the Institutional Review Board of Ponce School of Medicine in Ponce. Recruitment began in June 2013, enrollment began in July 2013, and the study was completed in September 2013. A short 30-day study period was chosen because the study was considered a proof-of-concept study.

Participants

Adults aged 21 years or older with high-sensitivity C-reactive protein (hs-CRP) values between 2 and 5 mg/L who were willing to maintain a stable diet during the study were recruited. Exclusion criteria included a body mass index (equal to weight in kilograms divided by height in meters squared) ≥45; recent weight change (at least 3 kg from the first visit to the end of the qualifying period 2 weeks later); nephrotic range proteinuria (at least 3 g/day); current or prior malignancy; history of bariatric surgery; long-term treatment (≥6 months) with antihypertensive or antidiabetic medications treatment, weight-loss drugs within the past 6 months; thyroid-stimulating hormone ≥1.5 times upper limit of normal; alanine aminotransferase or aspartate aminotransferase 3 times the upper limit of normal; unexplained creatine kinase (CK) concentration 3 or more times the upper limit of normal; or creatine kinase increase from known muscle disease. After informed consent by a research associate, a baseline questionnaire was administered to collect data on age, gender, weight, current prescription medications, foods favored during weekdays and weekends, frequency of exercise, history of major diseases and major medical problems, and use of supplements or vitamins in the past month. These metrics were not collected again at follow-up. Blood pressure and heart rate were determined by automated sphygmomanometer with the patient sitting and resting quietly for 5 minutes. A baseline fasting lipid profile, thyroid-stimulating hormone, complete metabolic panel, and hs-CRP levels were obtained for all participants. Participants received a $25 stipend for travel during their participation in the study.

Sample size determination

Based on variance findings from a prior small unpublished open label study, the sample size of 60 participants was estimated to provide 80% power to detect a 20% reduction in hs-CRP in the experimental group compared with control.

Randomization and blinding

Sixty participants, stratified by gender, were randomly allocated by computer-generated random numbers in a 1:1 ratio to either the intervention or placebo arm. Participants and the principal investigator (L.M.) were blinded to whether each participant received supplement or placebo.

Intervention

The experimental fat preparation used in this study was 52.5% *cis*-palmitoleic acid, as determined by independent

Table 1 Fatty acid profile of experimental and placebo supplements*

Common name	Lipid number	Experimental supplement (%)	Placebo supplement (%)
Caprylic	C 8:0		54.61
Pelargonic	C 9:0		0.12
Capric	C 10:0		45.11
Lauric	C 12:0		0.10
Myristic	C 14:0	1.62	
Pentadecanoic	C 15:1	0.62	
Palmitoleic	C 16:1	52.50	
Margaric	C 17:0	10.12	
Margaroleic	C 17:1	9.80	
Stearic	C 18:0	5.63	
Oleic	C 18:1	4.99	
Linoleic	C 18:2	1.42	
Linolenic	C 18:3	1.46	
Arachidic	C 20:0	3.50	
Other fatty acids		6.66	0.05

*Each experimental capsule contained 420 mg of oil and each placebo capsule contained 1000 mg of oil. Thus, 52.5% of palmitoleic acid equals 220.5 mg of palmitoleic acid per capsule. All individual identified fatty acid constituents in experimental and placebo supplements in quantities greater than 0.5% are shown.

analysis (Barrow-Agee Laboratories, Memphis, [illegible]) (Table 1). The supplemental fat was obtained by dou[illegible] metabolically distilling anchovy oil after the removal [illegible] omega-3s, including eicosapentaenoic acid [illegible]osahex[illegible]aenoic acid. Participants in the interven[illegible] (exp[illegible]mental) group received capsules containing 220[illegible]g of [illegible] acid. Those in the control group re[illegible]ved [illegible]al capsules with 1000 mg of medium [illegible]n triglyc[illegible]s (MCT) (Table 1). MCT was chosen [illegible]nert control [illegible]ause it would not affect participants' leve[illegible]f hs-CRP, LDL, or HDL. The amount of M[illegible]T was chose[illegible] that the capsules were identical in s[illegible] and [illegible]ppearance t[illegible] the palmitoleic acid capsules. A[illegible] partici[illegible]nts were instructed to take 1 capsule per day w[illegible]eals. Al[illegible]apsules were sourced from the s[illegible]rug c[illegible]any [illegible]d made to look as much alike as [illegible]ossib[illegible] Neithe[illegible]ysician nor study staff saw the c[illegible]tles, w[illegible]h were given to participants in sealed bottles. Co[illegible]li[illegible]e in[illegible] study arm was assessed by collecting bottle[illegible] the end of the study.

Outcomes and statistical analyses

After completion of the 30-day study period, fasting lipid profiles and hs-CRP levels were measured. All blood draws were carried out at a Clinical Laboratory Improvement Amendments –certified laboratory in Ponce. All 30 participants in each arm provided baseline and 30-day follow-up data. The primary outcome was change in hs-CRP and the secondary outcomes were changes in triglyceride (TG), LDL, and HDL. The study protocol was written to include participants with hs-CRP between 3 and 10 mg/dL; however, before the recruitment began, it was decided to change this to mild systemic inflammation with hs-CRP between 2 and 5 mg/dL. There were no changes to the protocol after initiation of recruitment.

Continuous variables were summarized using means and standard deviations. *P* values for the differences between intervention and control groups at baseline were determined by Wilcoxon rank sum test for weight given its non-normal distribution, 2 sample t-tests for other continuous variables, and chi-square test for [illegible]der. Treatment effect estimates were determined usi[illegible]nary [illegible]f covariance models of the mean difference[illegible]tween wit[illegible]group net changes of hs-CRP and fasting li[illegible] adjusted [illegible]r baseline levels of each biomarker. [illegible]imates [illegible]ercen[illegible]ange were determined by dividi[illegible]he effect est[illegible]by the mean baseline value of ea[illegible]oma[illegible]. Althoug[illegible] none of the participants reporte[illegible]any [illegible]ous di[illegible]r lifestyle changes during the c[illegible]se of the [illegible]udy, [illegible]tailed assessments of diet and li[illegible]habits were [illegible]aken and therefore could not cont[illegible]led f[illegible]n the statistical models. In sensitivity analyses, analysis [illegible]ovariance models were constructed a[illegible]g for potential [illegible]nfounders of the effect of palmitoleic acid on hs-CRP and fasting lipids, including baseline [illegible]ight, age, [illegible]d gender. All tests were 2-sided with a *P* [illegible]ue $< .0$[illegible] considered statistically significant.

[illegible]ts

Thirty participants were randomly allocated to intervention, 30 to control, all participants received the intended treatment, and all were analyzed for the primary outcome (Fig. 1). All supplement and placebo bottles were returned empty to study coordinator at study completion. Baseline characteristics of participants are shown in Table 2. Participants were 17-70 years of age (mean, 45 years) and 63% were female. Intervention and control groups differed slightly in baseline heart rate and systolic blood pressure, but because these characteristics were not thought to influence response to the supplement or placebo, they were not factored into the analyses of treatment effect. Baseline and 30-day lipid and inflammatory marker values are shown in Table 3. Both groups were dyslipidemic (LDL ≥ 100) with evidence of systemic inflammation (CRP ≥ 3). There were no significant differences between groups in lipid or inflammatory markers at baseline. At 30 days, there were significant mean (95% confidence interval [CI]) reductions in CRP (−1.9 [−2.3 to −1.4] mg/L), TG (−30.2 [−40.2 to −25.3] mg/dL), and LDL (−8.9 [−12.0 to −5.8] mg/dL), and a significant increase in HDL (2.4 [1.5 to 3.3] mg/dL) in the intervention group compared with control. These changes equated to 44%, 15%, and 8% reductions in CRP, TG, and LDL, respectively, and a 5% increase in HDL compared with control.

In sensitivity analyses with additional adjustment for baseline weight, age, and gender, the mean (95% CI) effect estimates were similar to the models adjusted solely for



Figure 1 Study flow diagram.

baseline biomarker values: CRP, −2.0 (−2.4 to −1.5) mg/L; TG, −30.1 (−41.1 to −19.1) mg/dL; LDL, −8.6 (−1.8 to −5.38) mg/dL; and HDL, 2.4 (1.4 to 3.3) mg/dL.

Two to 3 participants in the intervention group developed gastrointestinal distress and 1 developed a headache during the study period. There were no reported effects or adverse effects in the control group.

Discussion

Diabetes and cardiovascular disease are leading causes of death worldwide, and strategies to reduce risk factors for their occurrence are needed. In the present study, we demonstrate that supplementation with purified palmitoleic acid in adults with dyslipidemia and systemic inflammation, 2 risk factors for cardiometabolic disease, leads to improved serum lipids and decreased inflammation. These findings add on a growing body of animal and epidemiological evidence on the potential benefits of palmitoleate.

Table Baseline characteristics of study participants*

	All (n = 60)	Intervention (n = 30)	Control (n = 30)	*P* value
Age (y)	45 (16)	45 (17)	45 (15)	.99
Gender (% female)	38 (63%)	19 (63%)	19 (63%)	1.00
Weight (lb)	192 (51)	179 (45)	204 (55)	.08
Heart rate (beats/min)	81 (8)	78 (6)	84 (8)	<.01
Blood pressure (mmHg)				
Systolic	117 (8)	115 (8)	120 (9)	.03
Diastolic	68 (6)	68 (7)	68 (6)	.96

*Mean (standard deviation) provided for continuous variables and n (%) for gender.

Human studies

In an early cross-sectional study, circulating palmitoleate (oral glucose tolerance test F ratio 8.2, $P = .005$; euglycemic hyperinsulinemic clamp F ratio 7.8, $P = .007$) but not total free fatty acids (oral glucose tolerance test F ratio 0.6, $P = .42$; clamp: F ratio 0.7, $P = .40$) correlated positively with insulin sensitivity, independent of age, sex, and adiposity.[15] In that study, with a 1-standard deviation increase in palmitoleate, the odds for being in the highest vs the lowest tertile of change in insulin sensitivity was 2.35 (95% CI 1.16 to 5.35). Subsequent epidemiological data suggested that circulating palmitoleate is involved in insulin sensitivity, cholesterol metabolism, and hemostasis, although the net cardiovascular effect may be mixed: lower LDL, higher HDL, lower fibrinogen, but higher triglycerides and *greater* insulin resistance, at least in men.[3] In other epidemiologic studies, higher intake of the *trans* isomer from dairy has been associated with lower levels of inflammation and a *lower* risk of diabetes, but mixed relationships to serum lipids.[4,5]

In most,[7-9] but not all,[6] studies, macadamia nuts are associated with more favorable serum lipid profiles, but investigations to date have been small (1 study of 71 participants, but typically fewer than 35 participants) and of short duration (3-4 weeks). Moreover, the dose of palmitoleate provided in these studies is difficult to ascertain given that interventions have provided, for instance, whole nuts (eg, 20 or 40 to 90 g/day)[8,9] or nut oil (eg, 62 g/day).[6] Assuming

Table 3 Baseline and 30-day biomarker values among experimental and control groups*

Biomarker	Intervention (n = 30)	Control (n = 30)	Effect estimate	*P* value
C-reactive protein (mg/L)				
Baseline	4.3 (0.2)	4.3 (0.1)		.88
30 day	2.1 (0.2)	4.0 (0.2)		<.001
			−1.9 (−2.3 to −1.4)	<.0001
Triglyceride (mg/dL)				
Baseline	202.4 (11.9)	210.6 (11.0)		.70
30 day	170.3 (9.6)	207.2 (10.7)		.01
			−30.2 (−40	<.0001
Low-density lipoprotein cholesterol (mg/dL)				
Baseline	114.1 (4.3)	119.6 (4.9)		.41
30 days	105.8 (3.7)	119.2 (4.3)		.02
			.9 (−12.0	<.0001
High-density lipoprotein cholesterol (mg/dL)				
Baseline	45.7 (1.0)	43.3 (1.0)		.10
30 days	47.1 (0.9)	42.7 (0.9)		<.001
			(1. .3)	<.0001

*Means (standard errors of the mean) shown for baseline and 30-day values; effect esti d ined by analy covariance adjusted for baseline levels of each biomarker (mean and 95% CI shown); *P* values for baseline, 30 days, and ect es s values represent between-group differences.

75-100 g of macadamia nuts as edible oil[9] and palmitoleate as 17% of total fat,[16] prior interventions have provided study participants between 2.5 and 11.5 g/day of palmitol levels far greater than those in the current study. Our d was based on preliminary, open label, nonrandomized, man dose–ranging studies (unpublished).

Animal and in vitro studies

Animal studies have shown be cial s of supplemental palmitoleate on liver plasma l [11,12] Cao et al. used quantitative lipide yses and mi eficient in adipose tissue lipid chap ones *a* nd *mal2* to identify palmitoleate as an adip tissue–deriv pid hormone that strongly stimulates uscle insulin actio and suppresses hepatosteatosis.[2] noth udy, one of the first with exogenous administrati mitole KK-Ay mice (a model for studies se ty dia s with low insulin sensitivity) ora admi d 300 mg/kg of palmitoleic acid 00 mg of palmitic acid daily for 4 weeks.[12] Palmitole duc y weight increase, ameliorated the developm f hyperglycemia and hypertriglyceridemia, and improve ulin sensitivity. In addition, liver weight, hepatic lipid accumulation, and hepatic triglyceride levels were lower in the palmitoleic acid group compared with the control (vehicle and palmitic acid) groups. Furthermore, palmitoleic acid down-regulated messenger RNA expressions of pro-inflammatory adipocytokine genes (tumor necrosis factor-α and resistin) in white adipose tissue as well as lipogenic genes (SREBP-1, FAS, and SCD-1) in liver.

In vitro studies have demonstrated that palmitoleate is cytoprotective and mitogenic,[17] inducing beta-cell proliferation and improving secretory function in animals[13] and humans.[14] After treatment of rat skeletal muscle cells with mitoleate, sal glucose uptake was enhanced approxi- ly 2-fold d associated with a rise in glucose oxidation and synthesis, neither of which could be attributed to activation of signaling proteins normally modulated by such as insulin, nutrients, or cell stress.[18] The increase in glucose uptake did involve an increase in the plasma membrane abundance of GLUT1 and GLUT4. In contrast, *palmitate* caused a substantial reduction in insulin signaling and insulin-stimulated glucose transport, but was unable to antagonize the increase in transport elicited by palmitoleate. These findings suggest that saturated and monounsaturated fats exert distinct effects on insulin signaling and glucose uptake.[18] Palmitoleate may also increase the insulin-inducible GLUT4 receptor by activation of peroxisome proliferator–activated receptor-gamma, the transcription factor strongly expressed in adipocytes. In fact, palmitoleic acid at 1 μM has been shown to induce a transcriptional activity that corresponds to half the therapeutic levels of the diabetes drug, rosiglitazone.[19]

Study strengths and limitations

Strengths of the current study include the randomized nature, blinding, placebo supplements matched in taste and appearance to the experimental supplements, and complete follow-up. Limitations include the small sample size, short duration, and absence of testing of plasma concentration of palmitoleic acid to assess baseline status or compliance with the intervention. In addition, lifestyle and dietary factors, which may impact serum lipids and hs-CRP, were not evaluated in detail, and measures of weight, foods favored during weekdays and weekends, and frequency of exercise were not collected at follow-up. However, given the randomized nature of the study,

potential confounders are anticipated to be evenly distributed between study arms.

Conclusion

In this randomized, double-blinded, placebo controlled trial, purified palmitoleic acid exerted potent anti-inflammatory and lipid-modulating effects compared with placebo. These findings build on a growing body of in vitro, animal, and human studies, demonstrating the importance of palmitoleic acid to regulating metabolism. Thus, purified palmitoleic may be a therapeutic approach in helping maintain lipid levels within a healthy range as well as improving inflammatory markers in patients with mild dyslipidemia and inflammation. Larger and longer term studies are needed to confirm these findings.

References

1. Olefsky JM. Fat talks, liver and muscle listen. *Cell*. 2008;134: 914–916.
2. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. *Cell*. 2008;134:933–944.
3. Mozaffarian D, Cao H, King IB, et al. Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes. *Am J [illegible] Nutr*. 2010;92:1350–1358.
4. Mozaffarian D, Cao H, King IB, et al. Trans-palmitoleic acid, [illegible]bolic risk factors, and new-onset diabetes in U.S. adults: a co[illegible] study. *Ann Intern Med*. 2010;153:790–799.
5. Mozaffarian D, de Oliveira Otto MC, Lemaitre R[illegible]s-Palmitoleic acid, other dairy fat biomarkers, and [illegible]dent d[illegible]tes: the Multi-Ethnic Study of Atherosclerosis (M[illegible]). *Am [illegible] Nutr*. 2013;97:854–861.
6. Nestel P, Clifton P, Noakes M. Effect[illegible] increas[illegible]etary palmitoleic acid compared with palmitic [illegible]leic acids on [illegible]a lipids of hypercholesterolemic men. *J Li[illegible]* [illegible]994;35:656–6[illegible]
7. Curb JD, Wergowske G, Dobbs JC, Abbott RD, Huang B. Serum lipid effects of a high-monounsaturated fat diet based on macadamia nuts. *Arch Intern Med*. 2000;160:1154–1158.
8. Hiraoka-Yamamoto J, Ikeda K, Negishi H, et al. Serum lipid effects of a monounsaturated (palmitoleic) fatty acid-rich diet based on macadamia nuts in healthy, young Japanese women. *Clin Exp Pharmacol Physiol*. 2004;31(Suppl 2):S37–38.
9. Garg ML, Blake RJ, Wills RB. Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. *J Nutr*. 2003;133:1060–1063.
10. Belitz H-D, Grosch W, Schieberle P. Edible Fats and Oils. In: Food Chemistry. Berlin, Germany: Springer, 20[illegible]
11. Shiba S, Tsunoda N, Wakutsu M, et al. [illegible]pid metabolism by palmitoleate and eicosapentaeno[illegible]d (EPA) in[illegible] fed a high-fat diet. *Biosci Biotechnol Biochem*. [illegible];75:2401–24[illegible]
12. Yang ZH, Miyahara H, Hatanak[illegible] Chro[illegible]ministrati[illegible] palmitoleic acid reduces insulin resista[illegible]d hepatic [illegible]ccu[illegible]on in KK-Ay Mice with genetic type 2 [illegible]etes. *Li[illegible]s Heal[illegible]* [illegible]011;10:120.
13. Maedler K, Spinas G[illegible]yntar [illegible]oritz W, K[illegible]ser N, Donath MY. Distinct effects [illegible] sat[illegible] monou[illegible]turated fatty acids on beta-cell turno[illegible]nd func[illegible] *Diabet[illegible]* [illegible]001;50:69–76.
14. Maedler K, [illegible]holzer J, Buc[illegible] S[illegible]s GA, Donath MY. Monounsaturated [illegible] prevent the [illegible]terious effects of palmitate and high glu[illegible]ose on [illegible]n pancreatic beta-cell turnover and function. *Diabetes*. 2003;52:[illegible]3.
15. [illegible]N, Kantartzis [illegible]elebi N, et al. Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. *Diabetes Care*. [illegible]0;33:405–407.
16. Maguire LS, [illegible]Sullivan SM, Galvin K, O'Connor TP, O'Brien NM. [illegible]ty acid pr[illegible], tocopherol, squalene and phytosterol content of wal[illegible], peanuts, hazelnuts and the macadamia nut. *Int J Food Sci Nutr*. 2004;55:171–178.
17. Diakogiannaki E, Dhayal S, Childs CE, Calder PC, Welters HJ, [illegible]gan NG. Mechanisms involved in the cytotoxic and cytoprotective actions of saturated versus monounsaturated long-chain fatty acids in pancreatic beta-cells. *J Endocrinol*. 2007;194:283–291.
18. Dimopoulos N, Watson M, Sakamoto K, Hundal HS. Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. *Biochem J*. 2006;399:473–481.
19. Sauma L, Stenkula KG, Kjolhede P, Stralfors P, Soderstrom M, Nystrom FH. PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids. *Nutrition*. 2006;22:60–68.

RETRACTED